Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Gil

Showing results (181-190 of 229) with videos related to

Pageof 23
Sort By:
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)Beatriz Tavira, Teresa Iscar, Luis Manso, et al.
International Journal of Molecular Sciences|February 9, 2020
Evaluating Face2Gene as a Tool to Identify Cornelia de Lange Syndrome by Facial PhenotypesAna Latorre-Pellicer, Ángela Ascaso, Laura Trujillano, et al.
Breast Cancer Research and Treatment|January 5, 2019
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 studyAlberto Ocana, Marta Gil-Martin, Silvia Antolín, et al.
Nature Communications|January 5, 2023
Adipose tissue is a source of regenerative cells that augment the repair of skeletal muscle after injuryQuentin Sastourné-Arrey, Maxime Mathieu, Xavier Contreras, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 3, 2019
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancerYolanda Garcia Garcia, Ana de Juan Ferré, Cesar Mendiola, et al.
Journal of Personalized Medicine|February 2, 2021
Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic AsthmaJosé A Cañas, Marcela Valverde-Monge, José M Rodrigo-Muñoz, et al.
Medicine|May 23, 2026
Baseline immune status associates respiratory viral infection in preterm infants: A prospective cohort studyJosé Antonio Cañas, José Manuel Rodrigo-Muñoz, Laura Sánchez-García, et al.
Frontiers in Immunology|December 15, 2025
Differential DNA methylation in infants with IgE- and non-IgE-mediated cow's milk allergy and its association with acquired toleranceRebeca López-Gómez, Marta Gil-Martínez, Ana Ladrón-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Pageof 23

Showing results (181-190 of 229) with videos related to

Sort By:
Pageof 23
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2023
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study)Beatriz Tavira, Teresa Iscar, Luis Manso, et al.
International Journal of Molecular Sciences|February 9, 2020
Evaluating Face2Gene as a Tool to Identify Cornelia de Lange Syndrome by Facial PhenotypesAna Latorre-Pellicer, Ángela Ascaso, Laura Trujillano, et al.
Breast Cancer Research and Treatment|January 5, 2019
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 studyAlberto Ocana, Marta Gil-Martin, Silvia Antolín, et al.
Nature Communications|January 5, 2023
Adipose tissue is a source of regenerative cells that augment the repair of skeletal muscle after injuryQuentin Sastourné-Arrey, Maxime Mathieu, Xavier Contreras, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 3, 2019
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancerYolanda Garcia Garcia, Ana de Juan Ferré, Cesar Mendiola, et al.
Journal of Personalized Medicine|February 2, 2021
Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic AsthmaJosé A Cañas, Marcela Valverde-Monge, José M Rodrigo-Muñoz, et al.
Medicine|May 23, 2026
Baseline immune status associates respiratory viral infection in preterm infants: A prospective cohort studyJosé Antonio Cañas, José Manuel Rodrigo-Muñoz, Laura Sánchez-García, et al.
Frontiers in Immunology|December 15, 2025
Differential DNA methylation in infants with IgE- and non-IgE-mediated cow's milk allergy and its association with acquired toleranceRebeca López-Gómez, Marta Gil-Martínez, Ana Ladrón-Guevara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human StudyDejan Juric, Jordi Rodon, Josep Tabernero, et al.
Pageof 23